key: cord-0903239-t1f8rbv2 authors: Rakhmat, Iis Inayati; Kusmala, Yudith Yunia; Handayani, Dewi Ratih; Juliastuti, Henny; Nawangsih, Eka Noneng; Wibowo, Arief; Lim, Michael Anthonius; Pranata, Raymond title: Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression date: 2021-04-01 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2021.03.027 sha: 03faabca890b9dbfaec0b829e9b8eb98b0c13986 doc_id: 903239 cord_uid: t1f8rbv2 BACKGROUND AND AIMS: This study aims to synthesize evidence on dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in COVID-19 patients and factors affecting it. METHODS: We performed a systematic literature search from PubMed, Scopus, and Embase databases from inception of databases up until 7 March 2021. Studies that met all of the following criteria were included: 1) observational studies or randomized controlled trials that report COVID-19 patients, 2) reporting DPP-4 inhibitor use, 3) mortality, and 4) mortality based on DPP-4 inhibitor use. The exposure was DPP-4 inhibitor, defined as DPP-4 inhibitor use that started prior to COVID-19 hospitalization. The control group was patients with no exposure to DPP-4 inhibitor. The outcome was mortality. The pooled effect estimate was reported as risk ratio (RR). RESULTS: There were 4,477 patients from 9 studies in this systematic review and meta-analysis. 31% of (15%, 46%) the patients use DPP-4 inhibitor. Mortality occurs in 23% (15%, 31%) of the patients. DPP-4 inhibitor was associated with lower mortality in patients with COVID-19 (RR 0.76 [0.60, 0.97], p = 0.030, I2: 44.5%, p = 0.072). Meta-regression analysis showed that the association between DPP-4 inhibitor and mortality was significantly affected by metformin (RR 1.02 [1.00, 1.04], p = 0.048) and angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use (RR 1.04 [1.01, 1.07], p = 0.006), but not age (p = 0.759), sex (reference: male, p = 0.148), and hypertension (p = 0.218). CONCLUSION: DPP-4 inhibitor use was associated with lower mortality in COVID-19 patients, and the association was weaker in patients who were also taking metformin and/or ACE inhibitors. Coronavirus disease 2019 has affected more than a hundred millions of people and causes more than a million death globally. [1] Although most COVID-19 patients have mild symptoms or even asymptomatic, there a significant proportion of patients that will experience multiple complications resulting in death. [2] Diabetes has been shown to increase mortality in patients with COVID-19. [3] During the pandemic, questions on whether we should discontinue drugs routinely used for other comorbidities such as hypertension and diabetes in patients hospitalized with COVID-19. Moreover, many drugs that have been touted for treating COVID-19 fails. Thus, more importantly, can we repurpose these drugs to reduce in-hospital mortality in patients with COVID-19? Dipeptidyl peptidase-4 (DPP-4) enzyme is a serine exopeptidase expressed in various tissues and plays a crucial part in the metabolism of glucose and insulin. Dipeptidyl peptidase-4 inhibitor inhibitor exerts anti-inflammatory, anti-fibrotic, and anti-adipogenic properties, which may be useful in delaying the progression to hyper-inflammation in severe COVID-19 cases. [4] [5] [6] A multicenter study have shown that DPP-4 inhibitor was associated with lower mortality [7] , while other studies did not. [8, 9] This study aims to synthesize evidence on DPP-4 inhibitor and mortality in COVID-19 patients and factors affecting it. This is a Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) compliant systematic review and meta-analysis. This study is registered in PROSPERO (CRD42021241347). Studies that met all following criteria were included: 1) observational studies or randomized controlled trials that reported COVID-19 patients, 2) reporting DPP-4 inhibitor use, 3) mortality, and 4) mortality based on DPP-4 inhibitor use. Studies that met one of the following criteria were excluded: 1) conference papers, 2) abstracts, 3) commentaries, and 4) letters. There was no language restriction. Two independent authors extracted studies for the first author, study design, sample size, age, sex, hypertension, statin use, metformin use, angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use, the exposure, and mortality. Discrepancies were resolved by discussion. Two independent authors performed risk of bias assessment of the included studies using the Newcastle-Ottawa Scale (NOS). Discrepancies that arose were resolved by discussion. The exposure was DPP-4 inhibitor, defined as DPP-4 inhibitor use that started prior to COVID-19 hospitalization. The control group was patients with no exposure to DPP-4 inhibitor. The outcome was mortality, defined as death/non-survivor. The pooled effect estimate was reported as risk ratio (RR). STATA version 16.0 was used to perform meta-analysis. We pooled the risk ratio (RR) for DPP-4 inhibitor use and mortality, calculated from each of the included studies using the Der-Simonian Laird random-effects meta-analysis. P-values below or equal to 0.05 was considered as statistically significant. Cochran's Q test and I 2 statistic tests were performed to assess heterogeneity, in which I 2 values above 50% and p-value below 0.10 indicates significant heterogeneity. Qualitative funnel-plot analysis and quantitative regression-based Egger's test were performed to evaluate the risk of publication bias and small-study effects. Meta-regression analysis was performed to evaluate the effect of age, sex, hypertension, ACEI/ARB use, and metformin use on the association between DPP-4 inhibitor and mortality. There were 4,477 patients from 9 studies in this systematic review and meta-analysis [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [ Figure 1 ]. 31% of (15%, 46%) the patients used DPP-4 inhibitor. Mortality occurs in 23% (15%, 31%) of the patients. Baseline characteristics of the included studies is available in Table 1 . Funnel-plot was asymmetrical [ Figure 3A ] and non-parametric trim-and-fill analysis showed that imputation of one study on the right side of the plot resulted in RR of 0.78 [0.609, 1.00] [ Figure 3B ]. There was no indication of small-study effects (p=0.745). In this pooled analysis, we found that DPP-4 inhibitor use was associated with lower mortality in COVID-19 patients. Meta-regression analysis showed that the association between DPP4 inhibitor use and reduced mortality was weaker in patients who were also taking metformin and/or ACE inhibitors. Metformin and ACE/ARB have been shown to reduce mortality in patients with COVID-19 [17, 18] , these drugs are frequently prescribed in patients with diabetes. Possible explanation is that, the benefit of DPP-4 inhibitor in terms of mortality is reduced by the presence of the two drugs. Further analysis of individual patient data is required to evaluate whether DPP-4 inhibitor benefit is independent of metformin and ACE/ARB use. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may use angiotensinconverting enzyme 2 (ACE2) receptor by binding its spike (S) glycoprotein to enter human cells. [19] It has also been observed that the human DPP-4/CD26 receptor can also be used [23, 24] DPP-4 inhibitor, also known as gliptin, is an oral hypoglycemic agent that normally used in treating diabetic people, which is one of the risk factors for developing severe SARS-CoV-2 infection. [3] A number of non-communicable diseases such as hypertension, cardiovascular and cerebrovascular disease, chronic kidney disease, and chronic lung disease are also World Health Organization. Weekly epidemiological update -9 Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression: Diabetes and COVID-19 DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19? COVID-19 and diabetes: Can DPP4 inhibition play a role? DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: A multicenter case-control retrospective observational study Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily Related Outcomes Among Patients With Type 2 Diabetes. Diabetes Care 2021:dc201824 Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucoselowering drugs: a nationwide cohort study Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID -19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19 Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a metaanalysis Elevated interleukin levels are associated with higher severity and mortality in COVID 19 -A systematic review, meta-analysis, and meta-regression A wave of non-communicable diseases following the COVID-19 pandemic Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19 Body Mass Index and Outcome in Patients with COVID-19: A Dose-Response Meta-Analysis Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis: Clinical Frailty Scale in COVID-19 The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis